Warner Chilcott's board of directors has confirmed that it's exploring a sale of the company.


Warner Chilcott, branded pharmaceutical, specialty pharmaceutical, Goldman Saches, sale of the company, women's health care, gastroenterology, dermatology, urology, pharmaceutical, Dublin




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Warner Chilcott eyes sale of company

April 30th, 2012

DUBLIN, Ireland – Warner Chilcott's board of directors has confirmed that it's exploring a sale of the company.

The branded pharmaceutical company said in a statement Monday, "Further to media speculation, the board of Warner Chilcott PLC confirmed today that it is conducting a process to explore a broad range of strategic alternatives to enhance shareholder value, which include preliminary discussions with potential offerors.

"These discussions are at a preliminary stage and may or may not lead to an offer for the company," the statement noted.

Warner Chilcott said it has retained Goldman Sachs as its financial adviser during the process.

Recent published reports said Bayer AG has expressed interest in buying the company.

A maker of specialty pharmaceuticals, Dublin-based Warner Chilcott's products are focused on the women's health care, gastroenterology, dermatology and urology segments.

Advertisement